← Galderma Group AG/ADR (GALDY) — catalysts, pipeline & price
Catalyst Dossier · compiled by CeliA 🧫
Galderma Group AG/ADR (GALDY)
Biotechnology · market cap $45.9B · as of 2026-07-10
Research and calibrated estimates, not financial advice — verify before acting.
Next catalyst
2026-10-26 (est.)
Phase 3
Pipeline
20
programs
Upcoming events
1
next 90d+
Dossier
Ready
cached
Non-US-listed company. Financial statements and forensic scores here come from US SEC filings (10-K/10-Q), which foreign issuers don’t file — those sections may be blank. The catalyst calendar, pipeline, approval odds, price context and (where covered) analyst targets still apply.
Galderma Group AG/ADR (GALDY) is a dermatology-focused company with a market cap of approximately $50.4B and a broad pipeline spanning acne, rosacea, actinic keratoses, prurigo nodularis, psoriasis, and aesthetics (botulinum toxin). The most near-term catalyst concentration is in nemolizumab, with three readouts estimated between August and October 2026 across Phase 2 and Phase 3 trials in Prurigo Nodularis, each carrying high importance scores.
The catalyst path
- 2026-10-26 (est.)Phase 3 · Nemolizumabimp 9/10
Pipeline
| Asset | Phase | Indication |
|---|---|---|
| MAL 16.8% cream | Phase 3 | Actinic Keratoses |
| Metvix and natural daylight PDT | Phase 3 | Actinic Keratoses |
| Adapalene BPO Gel standard daily overnight application | Phase 3 | Acne |
| botulinum toxin neuromodulator | Phase 3 | Glabellar Lines |
| Metvix Cream 160 mg/g | Phase 2 | Photoaged Skin |
| Epiduo vehicle gel | Phase 2 | Acne |
| OnabotulinumtoxinA | Phase 3 | Moderate to Severe Glabellar Lines |
| Azelaic acid 15% Gel | Phase 3 | Papulopustular Rosacea (PPR) |
| CD5789 (trifarotene) | Phase 3 | Acne Vulgaris |
| Calcitriol 3mcg/g | Phase 2 | Chronic Plaque Psoriasis |
| CD14152 Dose A | Phase 2 | Prurigo Nodularis |
| AbobotulinumtoxinA | Phase 3 | Glabellar Frown Lines |
| Adapalene Lotion Vehicle | Phase 3 | Acne Vulgaris |
| CD5024 0.3% cream | Phase 2 | Atopic Dermatitis |
| CD11301 0.03% | Phase 2 | Cutaneous T Cell Lymphoma |
| CD0271 | Phase 3 | Acne Vulgaris |
| 0.18% COL-118 facial gel (1.8 mg brimonidine) | Phase 2 | Erythematous Rosacea |
| Metvix cream | Phase 3 | Basal Cell Carcinoma |
| CD5789 (trifarotene) 50μg/g cream | Phase 3 | Acne Vulgaris |
| C. propionate - Corticosteroid 1 | Phase 3 | Scalp Psoriasis |
Price & technical context
3-month
-10.6%
6-month
+1.6%
12-month
+15.5%
52-wk range
$34.00–$46.19
vs 50-day MA
-4.3%
vs 200-day MA
-2.7%
Realized vol
31.4%
Max drawdown
-31.8%
Daily closes through 2026-09-30. Realized vol annualized; max drawdown over ~2 years.
The full dossier is a Pro feature
Thesis, bull & bear, the if-approved scenario, financials, smart-money signals and risks — compiled by CeliA. The catalyst path & pipeline above are free.
Sources & data
- SEC filings — EDGAR filings for GALDY (10-K, 10-Q, S-3, 13D/G, Form 4)
- Clinical trials — 20 registered trials on ClinicalTrials.gov (per-trial NCT links in the pipeline)
- Market & financial data — SEC EDGAR (XBRL filings, Form 4), Yahoo Finance, Nasdaq — prices, statements, key metrics, insider & institutional filings.
- Regulatory — openFDA, FDA advisory & PDUFA calendars.
Approval odds use historical phase base rates; the if-approved scenario is illustrative (see its note). Figures trace to the sources above — verify before acting.
Data from CatalystAlert (ClinicalTrials.gov, SEC EDGAR, openFDA, market-data providers). Compiled by CeliA. Not financial advice.